Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Bolt Biotherapeutics, retaining the price target of $7.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors related to Bolt Biotherapeutics’ innovative approach and financial performance. Bolt’s lead asset, BDC-4182, is a Claudin 18.2-targeted immune stimulatory antibody conjugate that stands out from other antibody-drug conjugates because it uses a toll-like receptor 7/8 agonist as its payload. This differentiation has shown superior anti-tumor activity in preclinical studies, even in challenging low-antigen-density models, and has led to complete regressions in immunologically cold tumors.
Financially, Bolt reported a narrower net loss than expected for the third quarter of 2025, with expenses also coming in below estimates. The company ended the quarter with a strong cash position, providing an operational runway into 2027. The valuation of Bolt is supported by a discounted cash flow analysis, factoring in a 20% probability of launch for BDC-4182 in specific cancer types, leading to a price target of $7 per share. However, potential risks include delays in data releases, negative efficacy outcomes, and competitive pressures.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $75.00 price target.